Highlights and Quick Summary
- Other investing activities for the quarter ending September 30, 2020 was $-8 Thousand (a -0.0% decrease compared to previous quarter)
- Year-over-year quarterly Other investing activities increased by 14.29%
- Annual Other investing activities for 2020 was $-24 Thousand (a -17.24% decrease from previous year)
- Annual Other investing activities for 2019 was $-29 Thousand (a -12.12% decrease from previous year)
- Twelve month Other investing activities ending September 30, 2020 was $-31 Thousand
Trailing Other investing activities for the last four month:
| 30 Sep '20 | — | — | — |
|---|---|---|---|
| $-31 Thousand | — | — | — |
Visit stockrow.com/ALNA
for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow
statement with 10 years of data, and state-of-the-art screener.
Historical Other investing activities of Allena Pharmaceuticals, Inc.
Most recent Other investing activitiesof ALNA including historical data for past 10 years.Interactive Chart of Other investing activities of Allena Pharmaceuticals, Inc.
Allena Pharmaceuticals, Inc. Other investing activities for the past 10 Years (both Annual and Quarterly)
(All values are in $ million)
| Year | Q1 | Q2 | Q3 | Q4 | Fiscal Year |
|---|---|---|---|---|---|
| 2020 | – | $-0.01 | $-0.01 | $-0.01 | $-0.02 |
| 2019 | – | – | – | $-0.01 | $-0.03 |
| 2018 | – | – | – | – | $-0.03 |
Business Profile of Allena Pharmaceuticals, Inc.
Sector: Healthcare
Industry: Biotechnology
Allena Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States. Its lead product candidate is ALLN-346, a novel and urate degrading enzyme for patients with hyperuricemia and gout in the setting of advanced chronic kidney disease. The company was incorporated in 2011 and is headquartered in Newton, Massachusetts.